$Applied DNA Sciences(APDN)$ Last 2 months I bough APDN in the .30's. Sold some cheap, didn't think it would lift-off so fast. Now my remaining is up over 500%. I think LUCD $LUCID DIAGNOSTICS INC.(LUCD)$ will follow a similar pop. When MolDx comes through, its good for $4-5. Then over the next 5 years, I can see $20/share
NVDA - one of the big tech companies trading for 40x revenue
I can only find one time in the last 30 years of one of the big tech companies trading for 40x revenue, where $NVIDIA Corp(NVDA)$ trades now. $Amazon.com(AMZN)$ on 1/11/1999 and for a few days later in '99. Over the next three years, AMZN stock would fall 90%.There's no precedent to this ending well.ImageAmazon was growing at 280% when it traded for 40x sales, so the actual NTM figure would have been about 15x. I don’t have estimates from ‘99 off hand.The bubble lasted another year+ for Amazon and the dot coms after this. So, very possible we keep inflating for a while. In fact, for now I would say there’s to reason to think NVIDIA won’t beat estimates. Sentiment change is harder to gauge.I won't be cove
$LUCID DIAGNOSTICS INC.(LUCD)$ At the end of the third quarter of 2022, 15 hedge funds in the database of Insider Monkey held stakes worth $99.5 million in Lucid Group, Inc. (NASDAQ:LCID), compared to 16 in the preceding quarter worth $173.7 million.On November 10, R.F. Lafferty analyst Jaime Perez maintained a Buy rating on Lucid Group, Inc. (NASDAQ:LCID) stock and lowered the price target to $17 from $19, noting that the company’s two financing agreements and its asset-based loan of $1 billion should provide enough financial flexibility to commence its expansion.
Lucid Group, Inc. (NASDAQ:LCID) is a technology and automotive company that develops electric vehicle (EV) technologies. The company said in a statement recently that it produced 2,282 vehicles at its Arizona factory in the third quarter. It delivered 1,398 vehicles to customers during the same period.$LUCID DIAGNOSTICS INC.(LUCD)$
Lucid$LUCID DIAGNOSTICS INC.(LUCD)$ stock has witnessed a sharp decline from November 2021 highs of $57.75. Being a quality growth stock, there is a temptation to accumulate at current levels of $17.While I am bullish on LCID stock with a long-term investment horizon, I believe that further correction might be on the cards. With a cautiously optimistic view, LCID stock can be considered for gradual accumulation in the range of $10 to $15.In terms of challenges, a key factor in the next few quarters is macro-economic headwinds. Lucid’s first model in the U.S. is a luxury sedan. The company also plans to launch luxury sedans in Europe later in 2022.With the possibility of a recession or stagflation in 2023, it’s likely that demand for premium EVs will
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.